Adicet Bio announces board changes and committee appointments

Adicet Bio, Inc., a Boston-based company trading on the Nasdaq Capital Market under the symbol ACET, recently announced changes to its board of directors following a filing with the Securities and Exchange Commission. Andrew Sinclair, Ph.D., a Class III member of the board, resigned from his position on the board, Audit Committee, and Nominating and Corporate Governance Committee, effective Friday.

This reduction in board size from seven to six members was not due to any disagreements with management or the company's operations. In response to Sinclair's departure, the board appointed Michael Grissinger to the Audit Committee, who was also named chairperson of the Nominating and Corporate Governance Committee. These changes were disclosed in a press release and detailed in the company's recent SEC filing.

In related news, several analysts have updated their ratings and price targets for Adicet Bio, citing positive developments in their prula-cel therapy.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.